Dashboard
Eli Lilly and Company
LLYNYSEFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 20Trial readoutClinicalTrials.gov
Eli Lilly completes observational study NCT02951598 on healthcare use and costs in early Alzheimer's disease.
- Nov 20Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 2 trial of Brenipatide for Major Depressive Disorder (NCT07928245, recruiting)
- Nov 20Trial initiationClinicalTrials.gov
Eli Lilly posts Phase 1 trial NCT07945314 for LY3839056 safety, tolerability and PK in healthy participants; status NOT_YET_RECRUITING.
- Nov 20Trial readoutClinicalTrials.gov
Phase 2 trial of tirzepatide in type 2 diabetes and obesity completed (NCT06037252).
- Nov 19Trial readoutClinicalTrials.gov
Eli Lilly completes Phase 1 study NCT07794592 comparing two administration methods of Olomorasib (LY3537982) in healthy participants.
- Nov 18Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 1 trial NCT07915245 of LY4247147 for obesity/overweight in otherwise healthy participants; status recruiting.
- Nov 18Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 1 trial NCT07339722 of LY4515100 in healthy participants (status: recruiting).
- Nov 18Trial initiationClinicalTrials.gov
Eli Lilly Phase 1 trial NCT07867340 of LY5625573 recruiting in healthy participants including Japanese/Chinese cohorts and those with inflammation.
- Nov 18Trial initiationClinicalTrials.gov
Eli Lilly Phase 1 trial NCT07881887 of LY4167586 in obesity/overweight with or without T2D status recruiting.
- Nov 18Trial initiationClinicalTrials.gov
Eli Lilly Phase 1 trial NCT07867327 of LY4515100 in healthy male participants now recruiting.
- Nov 18Trial initiationClinicalTrials.gov
Phase 3 trial NCT07881458 of EloraTZP in adults with obesity/overweight and type 2 diabetes begins recruiting.
- Nov 18Trial initiationClinicalTrials.gov
Eli Lilly Phase 1 trial NCT07843459 of LY4560736 recruiting in healthy participants and Alzheimer's disease patients.
- Nov 18Trial initiationClinicalTrials.gov
Eli Lilly Phase 1 trial NCT07945314 for LY3839056 in healthy participants, status not yet recruiting.
- Nov 17OtherClinicalTrials.gov
Phase 3 trial NCT06297603 (retatrutide in T2D with renal impairment) status updated to ACTIVE_NOT_RECRUITING.
- Nov 17Trial initiationClinicalTrials.gov
Eli Lilly Phase 1 trial NCT07738614 of Eloralintide (LY3841136) in obesity/overweight updated to ACTIVE_NOT_RECRUITING.
- Nov 17Trial readoutClinicalTrials.gov
Phase 1 trial NCT07701083 of Eloralintide (LY3841136) in healthy participants completed.
- Nov 17Trial initiationClinicalTrials.gov
Eli Lilly initiates Phase 1 trial NCT07787182 of LY4405094 in healthy participants and Alzheimer's disease patients.
- Nov 17Trial initiationClinicalTrials.gov
Phase 1 trial NCT07914738 of Lepodisiran (LY3819469) in high Lipoprotein(a) participants updated to recruiting status.
- Nov 17Trial initiationClinicalTrials.gov
Phase 3 trial NCT07881432 initiated for EloraTZP in obesity without Type 2 diabetes; status NOT_YET_RECRUITING.
- Nov 17Trial readoutClinicalTrials.gov
Completed Phase 1 study NCT07426380 of Eloralintide (LY3841136) in renal impairment and normal renal function participants.
Not financial advice — research and opinion only. Disclosures